The 53 references in paper V. Arkhipov V., D. Arkhipova E., В. Архипов В., Д. Архипова Е. (2014) “ЗНАЧЕНИЕ ЭПИДЕМИОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ В ПУЛЬМОНОЛОГИИ // A ROLE OF EPIDEMIOLOGICAL STUDIES IN PULMONOLOGY” / spz:neicon:pulmonology:200

1
Travers J., Marsh S., Caldwell B. et al.External validity of randomized controlled trials in COPD. Respir Med. 2007; 101 (6): 1313–1320.
(check this in PDF content)
2
Tashkin D.P., Celli B., Senn S. et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.
(check this in PDF content)
3
Tonnel A.B., Perez T., Grosbois J.M. et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3(2): 301–310.
(check this in PDF content)
4
Fležar M., Jahnz-Rózyk K., Enache G. et al. SOSPES: SPIRIVA®observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe. Int. J. COPD 2013; 8: 483–492.
(check this in PDF content)
5
Lisspers K., Larsson K., Ställberg B. et al. COPD in primary care in Sweden – an 11 years epidemiological register study. ERS 2012; Abs. 4339.
(check this in PDF content)
6
Szafranski W., Cukier A., Ramirez A. et al.Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.
(check this in PDF content)
7
Soriano J.B., Kiri V.A., Pride N.B., Vestbo J.Inhaled corticosteroids with / without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am. J. Respir. Med. 2003; 2 (1): 67–74.
(check this in PDF content)
8
Calverley P., Pauwels R., Vestbo J. et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.
(check this in PDF content)
9
Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.
(check this in PDF content)
10
Vestbo J., Anderson J. A., Calverley P. M. et al.Bias due to withdrawal in long-term randomized trials in COPD: evidence from the TORCH study. Clin. Respir. J. 2011; 5: 44–49.
(check this in PDF content)
11
Suissa S. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 322–323.
(check this in PDF content)
12
Lachin J.M.Statistical considerations in the intent-to-treat principle. Control. Clin. Trials. 2000; 21 (3): 167–189.
(check this in PDF content)
13
Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338.
(check this in PDF content)
14
Miles M.C., Donohue J.F., Ohar J.A.Combination therapy for COPD: emerging evidence from recent clinical trials. Clin. Invest. 2011; 1 (6): 879–890.
(check this in PDF content)
15
Suissa S., Ernst P., Vandemheen K.L., Aaron S.D.Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 2008; 31: 927–933.
(check this in PDF content)
16
Wedzicha J.A., Calverley P.M., Seemungal T.A. et al.The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26.
(check this in PDF content)
17
Suissa S.Methodologic shortcomings of the INSPIRE randomized trial. Am. J. Respir. Crit. Care Med. 2008; 178 (10): 1090–1091.
(check this in PDF content)
18
Tonelli M.R., Curtis J.R., Guntupalli K.K. et al.An official multi-society statement: The role of clinical research results in the practice of critical care medicine. Am. J. Respir. Crit. Care Med. 2012; 185 (10): 1117–1124.
(check this in PDF content)
19
MacPherson H.Pragmatic clinical trials. Complement Ther. Med. 2004; 12 (2–3): 136–140.
(check this in PDF content)
20
Vogelmeier C., D'Urzo A., Pauwels R. et al. Budesonide / formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26: 819–828.
(check this in PDF content)
21
Suissa S., Ernst P., Boivin J.F. et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am. J. Respir. Crit. Care Med. 1994; 149 (3, Pt 1): 604–610.
(check this in PDF content)
22
Suissa S., Ernst P., Benayoun S. et al.Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332–336.
(check this in PDF content)
23
Sears M.R., Taylor D.R. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994; 11 (4): 259–283.
(check this in PDF content)
24
Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67 (11): 957–963.
(check this in PDF content)
25
http://www.cebm.net/index.aspx?o=8117
(check this in PDF content)
26
http://www.cebm.net/mod_product/design/files/CEBMLevels-of-Evidence-2.1.pdf
(check this in PDF content)
27
Larsson K., Janson C., Lisspers K. et al.Combination of budesonide / formoterol more effective than fluticasone / salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J. Intern. Med. 2013; 273 (6): 584–594.
(check this in PDF content)
28
Janson C., Larsson K., Lisspers K.H. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2-agonist: observational matched cohort study (PATHOS). Br. Med. J. 2013; 346: f3306. Doi: 10.1136/ bmj.f3306.
(check this in PDF content)
29
Joffe M.M., Rosenbaum P.R.Invited commentary: propensity scores. Am. J. Epidemiol. 1999; 150: 327–233.
(check this in PDF content)
30
Perkins S.M., Tu W., Underhill M.G. et al. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol. Drug Saf. 2000; 9: 93–101. http:// www.pulmonology.ru89
(check this in PDF content)
31
Battram C., Charlton S.J., Cuenoud B. et al.In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J. Pharmacol. Exp. Ther. 2006; 317 (2): 762–770.
(check this in PDF content)
32
Partridge M.R., Schuermann W., Beckman O. et al. Effect on lung function and morning activities of budesonide / formoterol versus salmeterol/fluticasone in patients with COPD. Ther. Adv. Respir. Dis. 2009; 3 (4): 1–11.
(check this in PDF content)
33
Lindberg A., Szalai Z., Pullerits T., Radeczky E.Fast onset of effect of budesonide / formoterol versus salmeterol / fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007; 12 (5): 732–739.
(check this in PDF content)
34
Borgström L., Asking L., Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int. J. Clin. Pract. 2005; 59 (12): 1488–1495.
(check this in PDF content)
35
Bisgaard H.,ed. Drug delivery to the lung. New York: Marcel Dekker, Inc. 2001. 437–438.
(check this in PDF content)
36
Vogelmeier C., Hederer B., Glaab T. et al.Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103.
(check this in PDF content)
37
Ek A., Larsson K., Siljerud S., Palmberg L.Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999; 54 (7): 691–699.
(check this in PDF content)
38
Pedersen S., O'Byme I.A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997: 52 (Suppl. 39): 1–34.
(check this in PDF content)
39
Miller-Larsson A., Jansson P., Runström A., Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162 (4, Pt 1): 1455–1461.
(check this in PDF content)
40
Zalacain R., Sobradillo V., Amilibia J. et al.Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13 (2): 343–348.
(check this in PDF content)
41
Wedzicha J.A., Brill S.E., Allinson J.P., Donaldson G.C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013; 11: 181.
(check this in PDF content)
42
Blais L., Forget A., Ramachandran S.Relative effectiveness of budesonide / formoterol and fluticasone propionate / salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin. Ther. 2010; 32 (7): 1320–1328.
(check this in PDF content)
43
Ferguson G.T., Anzueto A., Fei R. et al.Effect of fluticasone propionate / salmeterol (250 / 50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir. Med. 2008; 102 (8): 1099–1108.
(check this in PDF content)
44
Calverley P.M.A., Dransfield M.T., Bourbeau J. et al. Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations. ERS congress abstract 2012. Abs. 2113; http://www.ers-education.org/ ersMade/abstract_print_12/main_frameset.htm
(check this in PDF content)
45
Halpin D.M., Gray J., Edwards S.J. et al. Budesonide / formoterol vs salmeterol / fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int. J. Clin. Pract. 2011; 65 (7): 764–774.
(check this in PDF content)
46
Sin D.D., Tashkin D., Zhang X. et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374 (9691): 712–719.
(check this in PDF content)
47
Sin D., Tashkin D., Radner F. et al.Risk of pneumonia related to budesonide use in COPD: An updated pooled analysis. ERS congress abstract 2012. Abs. 2117; http:// www.ers-education.org/ersMade/abstract_print_12/main_frameset.htm
(check this in PDF content)
48
Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029–1036.
(check this in PDF content)
49
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146 (8): 545–555.
(check this in PDF content)
50
FitzGerald J.M., Boulet L.P., Follows R.M.The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol / fluticasone propionate with an adjustable maintenance dosing regimen of formoterol / budesonide in adults with persistent asthma. Clin. Ther. 2005; 27 (4): 393–406.
(check this in PDF content)
51
Guyatt G., Cairns J., Churchill D. et al.Evidence-based medicine. A new approach to teaching the practice of medicine. J.A.M.A. 1992; 268 (17): 2420–2425.
(check this in PDF content)
52
Sackett D.L., Rosenberg W.M., Gray J.A. et al.Evidence based medicine: what it is and what it isn't. Br. Med. J. 1996; 312 (7023): 71–72.
(check this in PDF content)
53
Valk P., Monninkhof E., van der Palen J. et al.Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166 (10):1358–1363. Информация об авторах А
(check this in PDF content)